EQL Pharma has recruited Carl Lindgren as Chief Business Development Officer. Carl replaces Alexander Brising, who was responsible for Business Development and built the company's pipeline since 2016, but now changes position within EQL to Chief Commercial Officer (CCO) with responsibility for the company's sales and marketing. Carl Lindgren has more than 30 years of experience in the pharmaceutical industry and comes most recently from a role as Vice President M&A/BD at Karo Healthcare (formerly Karo Pharma), which during Carl's time has grown from approx.

SEK 350m to approx. 4.5bn in annual turnover. In addition to having been deeply involved in Karo Healthcare's organic growth, Carl has also been responsible for and carried out a number of successful acquisitions.

Carl Lindgren takes up his position as CBDO at EQL in August 2023.